|
1
|
Sieradzki JC: Diabetes mellitusSzczeklik's
Internal Medicine. Szczeklik A and Gajewski P: Medycyna Praktyczna,
Kraków; pp. 1353–1402. 2014, (In Polish).
|
|
2
|
Matyszewski A, Czarnecka A, Solarek W, et
al: Molecular basis of carcinogenesis in diabetic patients
(Review). Int J Oncol. 46:1435–1443. 2015.PubMed/NCBI
|
|
3
|
World Health Organization, . Obesity and
overweight. http://www.who.int/mediacentre/factsheets/fs311/en/Accessed.
November 30–2010
|
|
4
|
International Diabetes Federation, .
Diabetes Atlas. 6th. http://www.idf.org/diabetesatlas/content/europe%3b%20Accessed.
November 30–2010
|
|
5
|
Polish Diabetes Association, . Clinical
recommendation concerning the management in patients with diabetes
in 2014. Clinical Diabetology. 3 (Suppl A):2014.http://www.cukrzyca.info.pl/zalecenia_kliniczne/zalecenie_kliniczne_dotyczace_postepowania_u_chorych_na_cukrzyce_2014In
Polish; Accessed. September 30–2014
|
|
6
|
Inzucchi SE, Bergenstal RM, Buse JB, et al
American Diabetes Association (ADA); European Association for the
Study of Diabetes (EASD): Management of hyperglycaemia in type 2
diabetes: A patient-centered approach: Position statement of the
American Diabetes Association (ADA) and the European Association
for the Study of Diabetes (EASD). Diabetes Care. 35:1364–1379.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Piątkiewicz P and Czech A: Glucose
metabolism disorders and the risk of cancer. Arch Immunol Ther Exp
(Warsz). 59:215–230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Currie CJ, Poole CD and Gale EA: The
influence of glucose-lowering therapies on cancer risk in type 2
diabetes. Diabetologia. 52:1766–1777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li D, Yeung SC, Hassan MM, Konopleva M and
Abbruzzese JL: Antidiabetic therapies affect risk of pancreatic
cancer. Gastroenterology. 137:482–488. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Landman GW, Kleefstra N, van Hateren KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin. Diabetes Care.
29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bowker SL, Yasui Y, Veugelers P and
Johnson JA: Glucose-lowering agents and cancer mortality rates in
type 2 diabetes: Assessing effects of time-varying exposure.
Diabetologia. 53:1631–1637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chong CR and Chabner BA: Mysterious
metformin. Oncologist. 14:1178–1181. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Buzzai M, Jones RG, Amaravadi RK, et al:
Systemic treatment with the antidiabetic drug metformin selectively
impairs p53-deficient tumor cell growth. Cancer Res. 67:6745–6752.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kisfalvi K, Eibl G, Sinnett-Smith J and
Rozengurt E: Metformin disrupts crosstalk between G protein-coupled
receptor and insulin receptor signaling systems and inhibits
pancreatic cancer growth. Cancer Res. 69:6539–6545. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gonzalez-Angulo AM and Meric-Bernstam F:
Metformin: A therapeutic opportunity in breast cancer. Clin Cancer
Res. 16:1695–1700. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rozengurt E, Sinnett-Smith J and Kisfalvi
K: Crosstalk between insulin/insulin-like growth factor-1 receptors
and G protein-coupled receptor signaling systems: a novel target
for the antidiabetic drug metformin in pancreatic cancer. Clin
Cancer Res. 16:2505–2511. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jorgensen LN, Dideriksen LH and Drejer K:
Carcinogenic Effect Of The Human Insulin Analog B10Asp In Female
Rats. Diabetologia. 35:A31992.
|
|
20
|
Kurtzhals P, Schäffer L, Sørensen A, et
al: Correlations of receptor binding and metabolic and mitogenic
potencies of insulin analogs designed for clinical use. Diabetes.
49:999–1005. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sciacca L, Cassarino MF, Genua M, et al:
Insulin analogues differently activate insulin receptor isoforms
and post-receptor signalling. Diabetologia. 53:1743–1753. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mayer D and Chantelau E: Treatment with
insulin glargine (Lantus) increases the proliferative potency of
the serum of patients with type-1 diabetes: a pilot study on MCF-7
breast cancer cells. Arch Physiol Biochem. 116:73–78. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hemkens LG, Grouven U, Bender R, et al:
Risk of malignancies in patients with diabetes treated with human
insulin or insulin analogues: A cohort study. Diabetologia.
52:1732–1744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jonasson JM, Ljung R, Talbäck M, Haglund
B, Gudbjörnsdòttir S and Steineck G: Insulin glargine use and
short-term incidence of malignancies - a population-based follow-up
study in Sweden. Diabetologia. 52:1745–1754. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Colhoun HMSDRN Epidemiology Group: Use of
insulin glargine and cancer incidence in Scotland: A study from the
Scottish Diabetes Research Network Epidemiology Group.
Diabetologia. 52:1755–1765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Home PD and Lagarenne P: Combined
randomised controlled trial experience of malignancies in studies
using insulin glargine. Diabetologia. 52:2499–2506. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rosenstock J, Fonseca V, McGill JB, et al:
Similar risk of malignancy with insulin glargine and neutral
protamine Hagedorn (NPH) insulin in patients with type 2 diabetes:
Findings from a 5 year randomised, open-label study. Diabetologia.
52:1971–1973. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dejgaard A, Lynggaard H, Råstam J and
Krogsgaard Thomsen M: No evidence of increased risk of malignancies
in patients with diabetes treated with insulin detemir: A
meta-analysis. Diabetologia. 52:2507–2512. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mannucci E, Monami M, Balzi D, et al:
Doses of insulin and its analogues and cancer occurrence in
insulin-treated type 2 diabetic patients. Diabetes Care.
33:1997–2003. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Heise T, Tack CJ, Cuddihy R, et al: A
new-generation ultra-long-acting basal insulin with a bolus boost
compared with insulin glargine in insulin-naive people with type 2
diabetes: A randomized, controlled trial. Diabetes Care.
34:669–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
U.S. Food and Drug Administration, .
Safety Alerts for Human Medical Products - Exubera (insulin human
rDNA origin) Inhalation Powder. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm085319.htmAccessed.
September 30–2014
|
|
32
|
Pro B and Dang NH: CD26/dipeptidyl
peptidase IV and its role in cancer. Histol Histopathol.
19:1345–1351. 2004.PubMed/NCBI
|
|
33
|
Wesley UV, McGroarty M and Homoyouni A:
Dipeptidyl peptidase inhibits malignant phenotype of prostate
cancer cells by blocking basic fibroblast growth factor signaling
pathway. Cancer Res. 65:1325–1334. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Masur K, Schwartz F, Entschladen F,
Niggemann B and Zaenker KS: DPPIV inhibitors extend GLP-2 mediated
tumour promoting effects on intestinal cancer cells. Regul Pept.
137:147–155. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Duntas LH: Clinical comments related to
medullary thyroid cancer diagnosis and management. Thyroid Res. 6
(Suppl 1):S62013.PubMed/NCBI
|
|
36
|
Chiu WY, Shih SR and Tseng CH: A review on
the association between glucagon-like peptide-1 receptor agonists
and thyroid cancer. Exp Diabetes Res. 2012:9241682012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vangoitsenhoven R, Mathieu C and Van der
Schueren B: GLP1 and cancer: Friend or foe? Endocr Relat Cancer.
19:F77–F88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arora S, Mehrotra A and Gulati SC:
Incretins and thiazolidinediones in glucose homeostasis and cancer:
Role of common polymorphisms. Cancer Lett. 323:128–134. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gier B, Butler PC, Lai CK, Kirakossian D,
DeNicola MM and Yeh MW: Glucagon like peptide-1 receptor expression
in the human thyroid gland. J Clin Endocrinol Metab. 97:121–131.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Waser B, Beetschen K, Pellegata NS and
Reubi JC: Incretin receptors in non-neoplastic and neoplastic
thyroid C cells in rodents and humans: relevance for incretin-based
diabetes therapy. Neuroendocrinology. 94:291–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Madsen LW, Knauf JA, Gotfredsen C, et al:
GLP-1 receptor agonists and the thyroid: C-cell effects in mice are
mediated via the GLP-1 receptor and not associated with RET
activation. Endocrinology. 153:1538–1547. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Waser B, Rehmann R, Sanchez C, Fourmy D
and Reubi JC: Glucose-dependent insulinotropic polypeptide
receptors in most gastroenteropancreatic and bronchial
neuroendocrine tumors. J Clin Endocrinol Metab. 97:482–488. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kissow H, Hartmann B, Holst JJ, et al:
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4
inhibition does not accelerate neoplasia in carcinogen treated
mice. Regul Pept. 179:91–100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Koehler JA, Kain T and Drucker DJ:
Glucagon-like peptide-1 receptor activation inhibits growth and
augments apoptosis in murine CT26 colon cancer cells.
Endocrinology. 152:3362–3372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
European Association for the Study of
Diabetes: Lantus insulin: a possible link with cancer which
requires further investigation. http://webcast.easd.org/press/glargine/glargine.htmAccessed.
September 30–2014
|
|
46
|
International Diabetes Federation, .
Statement from the International Diabetes Federation Related to
Studies Published in Diabetologia Suggesting Possible Link Between
Insulin Glargine and Cancer. http://www.idf.org/statement-international-diabetes-federation-related-studies-published-diabetologia-suggesting-possibAccessed.
September 30–2014
|
|
47
|
American Diabetes Association, . Studies
Find No Increase in Cancer Risk from Insulin Glargine. http://www.diabetes.org/newsroom/press-releases/2012/sci-sessions-insulin-cancer.htmlAccessed.
September 30–2014
|
|
48
|
Matuszek B, Lenart-Lipińska M and
Nowakowski A: Incretin hormones in the treatment of type 2
diabetes. Part II. Incretins - new possibilities for
pharmacotherapy of type 2 diabetes. Endokrynol Pol. 59:322–329.
2008.(In Polish). PubMed/NCBI
|
|
49
|
Znaniecka M, Rutkowska J and
Bandurska-Stankiewicz E: A new direction in the treatment of
diabetes - inncretinomimetics and DPP-4 inhibitors. Przegląd
Kardiodiabetologiczny. 5:171–181. 2010.(In Polish).
|
|
50
|
Labuzek K, Kozłowski M, Szkudłapski D,
Sikorska P, Kozłowska M and Okopień B: Incretin-based therapies in
the treatment of type 2 diabetes - more than meets the eye? Eur J
Intern Med. 24:207–212. 2013. View Article : Google Scholar : PubMed/NCBI
|
